

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

REMARKS

The Specification has been amended to identify Figures 12A-12D, which was inadvertently omitted. Support for this amendment can be found in Figure 12 and in the Specification, for example, at page 26, lines 21-26. Additionally, this information is also present in the parent application, serial number 08/954/279, which is incorporated by reference in the present application.

No new matter has been added.

Information Disclosure Statement

An Information Disclosure Statement (IDS) was filed on December 5, 2001. Entry of the IDS is respectfully requested.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned at (978) 341-0036.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Anne I. Craig
Anne I. Craig
Registration No. 32,976
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, Massachusetts 01742

Dated: 4/3/02

MARKED UP VERSION OF AMENDMENTSSpecification Amendments Under 37 C.F.R. § 1.121(b)(1)(iii)

Replace the paragraph at page 5, lines 31 through 33 with the below paragraph marked up by way of bracketing and underlining to show the changes relative to the previous version of the paragraph.

[Figure 12] Figures 12A-12D is a set of graphs illustrating that DNP-HSA induces IgE-mediated degranulation in four different cell lines (untransfected RBL-2H3, Figure 12A; RBL-A10, Figure 12B; RBL-D10, Figure 12C; and RBL-H11, Figure 12D), and that this degranulation is inhibitable by anti-CD81 mAb 5D1.